Jupiter Life Line Hospitals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 09, 2025.
JLHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved audited consolidated and standalone financial results for FY25 and unaudited results for Q4 FY25, with an unmodified audit opinion from statutory auditors. Consolidated revenue from operations stood at ₹1,073.44 crore versus ₹1,060.00 crore in FY24 (~1.3% growth), while profit after tax was ₹176.61 crore versus ₹151.95 crore (~16.2% growth). Standalone revenue grew ~12.7% YoY to ₹1,060.00 crore with PAT of ₹183.85 crore (~21% growth). A dividend of ₹1 per share (10% on face value of ₹10) has been recommended for FY25, subject to shareholder approval. The Board also approved the amalgamation of wholly-owned subsidiary Medulla Healthcare Private Limited into the company, appointed Dr. Ankit Thakker as Joint Managing Director & CEO for 5 years effective July 11, 2025, and named Mr. Sivasis Sen as the new CFO effective May 12, 2025.
The results show steady but modest revenue growth on consolidated basis with healthy double-digit PAT growth on standalone basis, which is broadly positive for shareholders. The recommended ₹1 dividend offers a modest payout, while the subsidiary amalgamation simplifies the group structure. Management reshuffling with a new CEO, CFO, and statutory auditor (KKC & Associates LLP) signals a strategic transition phase worth monitoring.